碳酸氢钠治疗重度代谢性酸血症与急性肾损伤:BICARICU-2随机临床试验
BICARICU-2随机对照试验在法国43个重症监护病房纳入640例重度代谢性酸血症(pH≤7.20)合并中重度急性肾损伤成人患者,比较静脉输注碳酸氢钠与不输注碳酸氢钠对第90天全因死亡率的影响;结果显示两组第90天全因死亡率无显著差异,碳酸氢钠组肾脏替代治疗使用比例较低。
要点
- 对于重度代谢性酸血症合并中重度急性肾损伤患者,静脉碳酸氢钠未影响第90天全因死亡率。
- 碳酸氢钠组第90天全因死亡率为62.1%(195/314),对照组为61.7%(193/313),绝对差0.4(95%CI -7.2至8.0;P=0.91)。
- 碳酸氢钠组肾脏替代治疗使用比例为35%(109/314),对照组为50%(157/313),绝对差-15.5(95%CI -23.1至-7.8)。
核心结论
- 对于重度代谢性酸血症合并中重度急性肾损伤患者,静脉碳酸氢钠未影响死亡率。
研究设计与样本
- 随机、开放标签临床试验,2019年10月6日至2023年12月19日在法国43个重症监护病房纳入640例患者,随访90天,末次随访日期为2024年6月17日。
- 纳入标准为成人重度代谢性酸血症(定义为pH≤7.20)合并中重度急性肾损伤。
- 患者按1:1随机接受静脉碳酸氢钠输注或不接受碳酸氢钠,目标动脉pH≥7.30。
主要发现
- 640例随机分组患者中627例纳入分析(对照组313例,碳酸氢钠组314例);中位年龄67岁(IQR 59-74岁);碳酸氢钠组314例中194例(62%)为男性,对照组313例中185例(59%)为男性。
- 主要分析中,碳酸氢钠组第90天全因死亡率为62.1%(195/314),对照组为61.7%(193/313),绝对差0.4(95%CI -7.2至8.0;P=0.91)。
- 第28天或第180天全因死亡率未见组间效应证据。
- 18项次要结局中,碳酸氢钠组肾脏替代治疗使用为35%(109/314),对照组为50%(157/313),绝对差-15.5(95%CI -23.1至-7.8)。
- 其他次要结局(包括不良事件)未见组间效应证据。
关键数值与推荐
- 重度代谢性酸血症定义为pH≤7.20。
- 碳酸氢钠输注目标为动脉pH≥7.30或更高。
- 第90天全因死亡率绝对差0.4(95%CI -7.2至8.0;P=0.91)。
- 肾脏替代治疗绝对差-15.5(95%CI -23.1至-7.8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effect of sodium bicarbonate infusion on outcome in patients with severe metabolic acidemia and moderate to severe acute kidney injury is unknown. OBJECTIVE: To determine whether sodium bicarbonate infusion is associated with day 90 all-cause mortality in patients with severe metabolic acidemia and moderate to severe acute kidney injury. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, clinical trial conducted with 640 patients in 43 French intensive care units from October 6, 2019, to December 19, 2023, with 90-day follow-up. The last date of follow-up was June 17, 2024. Adults with severe metabolic acidemia (defined as pH ≤7.20) and moderate to severe acute kidney injury were enrolled. INTERVENTION: Patients were randomized 1:1 to receive either intravenous sodium bicarbonate infusion or no sodium bicarbonate to target an arterial pH of 7.30 or higher. MAIN OUTCOMES AND MEASURES: The primary outcome was day 90 all-cause mortality. Secondary outcomes included day 28 and day 180 all-cause mortality; use of organ support therapy, vasopressors, or invasive mechanical ventilation; intensive care unit and hospital length of stay; intensive care unit-acquired infections; fluid balance; day-7 Sequential [Sepsis-related] Organ Failure Assessment score (6 organ systems' function is evaluated and scored from 0 [no dysfunction] to 4 [failure]; total score ranges from 0 [normal] to 24 [maximum failure]); and major adverse kidney events on day 90. RESULTS: Among 640 randomly assigned patients, 627 were analyzed (313 in the control group and 314 in the bicarbonate group). The median age was 67 years (IQR, 59-74 years); 194 of 314 patients (62%) in the bicarbonate group and 185 of 313 controls (59%) were male. In the primary analysis, day 90 all-cause mortality was 195 of 314 patients (62.1%) in the bicarbonate group and 193 of 313 (61.7%) in the control group (absolute difference, 0.4; 95% CI, -7.2 to 8.0; P = .91). There was no evidence of a group effect on day 28 or day 180 all-cause mortality. Among 18 secondary outcomes, kidney replacement therapy was used in 109 of 314 (35%) bicarbonate group patients and 157 of 313 (50%) controls (absolute difference, -15.5; 95% CI, -23.1 to -7.8). No evidence of a group effect was found on other secondary outcomes, including adverse events. CONCLUSIONS AND RELEVANCE: For patients with severe metabolic acidemia and moderate to severe acute kidney injury, intravenous sodium bicarbonate did not affect mortality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04010630.
引用
- Jung B, Jabaudon M, De Jong A, et al. Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial. JAMA. 2025. PMID: 41159812. doi:10.1001/jama.2025.20231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。